New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
08:18 EDTSGMOSangamo price target raised to $27 from $22 at Wedbush
Wedbush raised its price target for Sangamo BioSciences to $27 saying the phase 1 results published in the New England Journal of Medicine suggest that the company's ZFN approach to treating HIV has broad acceptance in the medical and scientific communities. The firm reiterats an Outperform rating on the stock.
News For SGMO From The Last 14 Days
Check below for free stories on SGMO the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
07:27 EDTSGMOIBC Life Sciences to hold a conference
Subscribe for More Information
September 10, 2014
07:06 EDTSGMOSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.
September 8, 2014
07:07 EDTSGMOSangamo reports positive clinical data of ZFP Therapeutic
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use